Mineralys Therapeutics Inc Dossier - Source-backed chat

Mineralys Therapeutics Inc

MLYSNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.78

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $23.72Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $2.1B

Enterprise Value $2B

Shares Outstanding 92.1M diluted

Next Earnings Date22 Dec 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Mineralys Therapeutics is a high-conviction, late-stage biopharmaceutical play focused on cardiorenal diseases driven by dysregulated aldosterone. Its lead candidate, lorundrostat, is a highly selective aldosterone synthase inhibitor targeting uncontrolled and resistant hypertension (uHTN/rHTN). With the FDA accepting its NDA and setting a PDUFA date for December 22, 2026, the company is transitioning from clinical-stage to commercial-stage. Backed by a robust balance sheet of $646.1 million in cash and investments (as of Q1 2026) and a newly secured $500 million debt facility, Mineralys is fully funded to execute its commercial launch and advance its pipeline in chronic kidney disease (CKD) and heart failure.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets8 analysts · as of 18 Aug 2026

Low · most bearish analyst$30.00

Mean target$48.50

High · most bullish analyst$56.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$30.00

The FDA issues a Complete Response Letter (CRL) or demands additional safety data regarding hyperkalemia risks, delaying approval by 12–18 months. Alternatively, post-approval commercial uptake is slow due to restrictive payer step-edits or intense competition from established cardiovascular giants, leading to a higher cash burn rate and potential dilutive equity raises.

Base CaseCentral scenario

$48.50

Matches the consensus mean

Lorundrostat receives FDA approval in December 2026. The commercial launch begins in early 2027, focusing initially on third- and fourth-line resistant hypertension patients. Payer coverage is established at parity with existing branded therapies, and the company achieves its projected launch milestones. The ADVANCE-HTN trial completes enrollment in H2 2026 and delivers positive top-line data in H1 2027, validating the drug's long-term clinical profile.

Bull CaseUpside scenario

$56.00

The FDA approves lorundrostat on or before the December 2026 PDUFA date with a clean label (minimal hyperkalemia warnings). Rapid commercial adoption is driven by strong physician interest and favorable payer coverage, capturing a significant share of the 10.3 million resistant hypertension patients in the US. Phase 3 ADVANCE-HTN trial readouts in H1 2027 show superior efficacy, and pipeline expansion into CKD and HFpEF progresses rapidly, driving substantial valuation expansion.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

De-risked clinical profile with robust Phase 3 Launch-HTN data demonstrating significant placebo-adjusted blood pressure reductions.
Strong balance sheet with $646.1 million in cash, cash equivalents, and investments as of March 31, 2026, providing a runway into 2028.
Clear regulatory path with FDA NDA accepted and PDUFA target action date set for December 22, 2026.
Significant market opportunity targeting over 10 million resistant hypertension patients in the US with high unmet medical needs.

Key Investment Risks

Binary regulatory risk associated with the upcoming FDA PDUFA decision in December 2026.
Commercial execution risk in a highly competitive cardiovascular market dominated by large pharmaceutical companies.
Potential safety concerns, specifically the risk of hyperkalemia (elevated potassium levels) in patients with comorbid chronic kidney disease.

Thesis Invalidation Triggers

FDA rejection (CRL) or significant delay of lorundrostat approval.
Failure of the ADVANCE-HTN Phase 3 trial to meet its primary efficacy endpoints.
Severe safety signals (e.g., high rates of hyperkalemia or off-target cortisol inhibition) emerging in ongoing trials or post-marketing surveillance.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.